Clinical Trials Logo
  1. Home
  2. Other
  3. NCT05325073

Erythropoietin Therapy to Induce Regulatory T Cells in Liver Transplant Recipients

Liver Transplant Rejection Clinical Trial

Official title:
Erythropoietin Therapy to Induce Regulatory T Cells in Liver Transplant Recipients

Clinical Trial Summary

The hypothesis of this proof-of-concept study is that EPO increases the frequency, stability and/or function of Tregs in liver transplant recipients. We also hypothesize that EPO will have a greater effect in everolimus vs. tacrolimus treated LTR, thus providing the rationale for a subsequent clinical trial to utilize EPO in combination with everolimus as a more successful pathway toward tolerance.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05325073
Study type Interventional
Source Northwestern University
Contact
Status Active, not recruiting
Phase Phase 4
Start date February 18, 2022
Completion date September 30, 2024
View Details
See also
  Status Clinical Trial Phase
Completed NCT01678937 - Immune Tolerance and Alloreactivity in Liver Transplant Recipients on Different Monotherapy Immunosuppressive Agents N/A
Completed NCT03781414 - Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Liver Transplant Recipients With Additional 12-month Follow-up and Long-term Extension Phase 2
Recruiting NCT02260375 - MSC Therapy in Liver Transplantation Phase 1
Not yet recruiting NCT04514666 - VOCs in Kidney and Liver Transplants N/A
Not yet recruiting NCT05335551 - TRU-IMMUNO: Optimizing Liver Immunosuppression
Completed NCT01745731 - Cell Infusion Intraportal Autologous Bone Marrow Mononuclear as Enhancer of Liver Regeneration Phase 2
Enrolling by invitation NCT05082077 - Global Utilization And Registry Database for Improved preservAtion of doNor Livers
Completed NCT06060808 - Role of NFKBIA and PTPN22 Genes Polymorphism in Acute Rejection Susceptibility After Living Donor Liver Transplantation in Egyptian Patients.
Completed NCT03874286 - The TOGETHER Project - Liver
Completed NCT04789213 - Mortality, Morbidity and Risk Factors of Liver Retransplantation
Recruiting NCT06400771 - Safety of DNP007 in Healthy Subjects Phase 1
Recruiting NCT03603548 - Comparison of Safety and Efficacy of Two Variants of Prolonged - Released Tacrolimus (Advagraf vs. Envarsus ) in Patients After Liver Transplantation : Single Center Randomised Control Trial N/A
Withdrawn NCT03315052 - Budesonide for Immunosuppression After Liver Transplantation to Reduce Side Effects Phase 4
Enrolling by invitation NCT05655273 - Conversion of Maintenance Prograf to Envarsus in Liver Transplant Recipients Phase 4
Recruiting NCT05707520 - Long-term Benefit of MPA in Liver Transplantation
Recruiting NCT04657562 - The New LC-MS/MS Method for Determination of Unbound Tacrolimus in Plasma
Completed NCT01444079 - Graft Rejection or Tolerance Affected by Serial Change of Anti-donor Lymphocyte Antibody After Liver Transplantation N/A
Active, not recruiting NCT06153641 - Cytokeratin 18 Non-invasive Biomarker for Rejection in Liver Transplant Patients